Virax Biolabs Group Stock Performance
| VRAX Stock | USD 1.94 0.20 9.35% |
Virax Biolabs holds a performance score of 5 on a scale of zero to a hundred. The entity has a beta of 1.4, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Virax Biolabs will likely underperform. Use Virax Biolabs Group sortino ratio, semi variance, as well as the relationship between the Semi Variance and rate of daily change , to analyze future returns on Virax Biolabs Group.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Virax Biolabs Group are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Virax Biolabs showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:10 | Last Split Date 2023-12-18 |
1 | Cosmos Health Holds EU Distribution Rights for Virax Biolabs Mpox Virus Real-Time PCR Detection Kits | 08/21/2024 |
2 | Virax Biolabs Announces Stock Offering What To Know | 08/22/2024 |
3 | Whats Going On With Virax Biolabs Stock Wednesday | 08/28/2024 |
4 | Virax Biolabs to Participate at 7th European Congress of Immunology | 08/29/2024 |
5 | Virax Biolabs extends distribution agreement to market Mpox detection kits | 09/16/2024 |
6 | Nasdaq Down 2 US Crude Stocks Increase | 10/23/2024 |
| Begin Period Cash Flow | 9.4 M |
Virax |
Virax Biolabs Relative Risk vs. Return Landscape
If you would invest 213.00 in Virax Biolabs Group on August 16, 2024 and sell it today you would lose (19.00) from holding Virax Biolabs Group or give up 8.92% of portfolio value over 90 days. Virax Biolabs Group is currently generating 1.571% in daily expected returns and assumes 23.1563% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Virax, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Virax Biolabs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Virax Biolabs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Virax Biolabs Group, and traders can use it to determine the average amount a Virax Biolabs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0678
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | VRAX | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 23.16 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.57 actual daily | 31 69% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Virax Biolabs is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Virax Biolabs by adding it to a well-diversified portfolio.
Virax Biolabs Fundamentals Growth
Virax Stock prices reflect investors' perceptions of the future prospects and financial health of Virax Biolabs, and Virax Biolabs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Virax Stock performance.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.5 | ||||
| Operating Margin | (42.54) % | ||||
| Current Valuation | 5.88 M | ||||
| Shares Outstanding | 4.34 M | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 59.40 X | ||||
| Revenue | 156.42 K | ||||
| Gross Profit | (1.36 K) | ||||
| EBITDA | (6.22 M) | ||||
| Net Income | (6.74 M) | ||||
| Cash And Equivalents | 21.76 K | ||||
| Total Debt | 224.3 K | ||||
| Current Ratio | 0.04 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (6.25 M) | ||||
| Earnings Per Share | (3.36) X | ||||
| Market Capitalization | 9.29 M | ||||
| Total Asset | 5.48 M | ||||
| Retained Earnings | (18.53 M) | ||||
| Working Capital | 4.21 M | ||||
About Virax Biolabs Performance
Evaluating Virax Biolabs' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Virax Biolabs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Virax Biolabs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 208.26 | 307.20 | |
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.22) | (1.16) | |
| Return On Assets | (1.23) | (1.29) | |
| Return On Equity | (1.25) | (1.19) |
Things to note about Virax Biolabs Group performance evaluation
Checking the ongoing alerts about Virax Biolabs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Virax Biolabs Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Virax Biolabs Group is way too risky over 90 days horizon | |
| Virax Biolabs Group may become a speculative penny stock | |
| Virax Biolabs Group appears to be risky and price may revert if volatility continues | |
| Virax Biolabs Group currently holds 224.3 K in liabilities. Virax Biolabs Group has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Virax Biolabs' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 156.42 K. Net Loss for the year was (6.74 M) with loss before overhead, payroll, taxes, and interest of (1.36 K). | |
| Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations. | |
| Latest headline from benzinga.com: Nasdaq Down 2 US Crude Stocks Increase |
- Analyzing Virax Biolabs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Virax Biolabs' stock is overvalued or undervalued compared to its peers.
- Examining Virax Biolabs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Virax Biolabs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Virax Biolabs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Virax Biolabs' stock. These opinions can provide insight into Virax Biolabs' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.